{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"JFZAQUNZQZASBL-AWEZNQCLSA-N","prefName":"MMB-FUBINACA (AMB-FUBINACA, FUB-AMB)","symbol":"MMB-FUBINACA","iupacName":"methyl (S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate","aliases":["AMB-FUBINACA","FUB-AMB"],"cas":"1715016-75-3","pubchemCid":"118791037","chebiId":null,"smiles":"CC(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CC3=CC=C(C=C3)F","molecularFormula":"C20H21FN3O3","molecularWeight":386.4,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/118791037"}},"classification":{"family":"scra","familyLabel":"Cannabinoïde synthétique (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origine (recherche pharmaceutique → marché illicite)","summaryFr":"Indazole-3-carboxamide à tête L-valine méthyl-ester et tail 4-fluorobenzyl","originNote":"Brevet Pfizer WO 2009/106980 (jamais commercialisé)","discovered":"2009"},"pharmacology":{"summaryFr":"MMB-FUBINACA (= AMB-FUBINACA = FUB-AMB) - indazole-3-carboxamide à tête L-valine méthyl-ester et queue 4-fluorobenzyl. Issu du brevet Pfizer WO 2009/106980. Banister et al. (ACS Chem Neurosci 2016) : Ki = 10,04 nM, EC50 = 0,54 nM (β-arrestine). Épidémie de Brooklyn du 12 juillet 2016 - 33 hospitalisations simultanées avec présentation « zombie » caractéristique (regard fixe, mouvements lents, mutisme) documentée par Adams et al. (NEJM 2017, PMID 29262413). France : **Arrêté 31 mars 2017** (NOR AFSP1710288A). CND **62/6** (mars 2019) → Annexe II Convention 1971.","receptorSummaryFr":"Agoniste complet CB1 (EC50 ≈ 0,54 nM β-arrestine ; Ki ≈ 10 nM) ; ≈ 85× THC","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":95,"reported":"EC50 ≈ 0,54 nM","confidence":"medium"},{"target":"CB2","efficacy":"full_agonist","relativeActivity":92,"reported":null,"confidence":"low"}],"references":[{"label":"Adams · NEJM 2017","pmid":"29262413","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/29262413/"},{"label":"Banister · ACS Chem Neurosci 2016","pmid":"27421060","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/27421060/"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Apaisement","description":"Détente du corps et de l'esprit ; baisse du bruit mental sans somnolence marquée.","intensity":15},{"key":"focus","label":"Clarté","description":"Attention soutenue et pensée claire ; lucidité fonctionnelle, pas d'euphorie.","intensity":10},{"key":"sleep","label":"Sommeil","description":"Effet sédatif : aide à l'endormissement et à la continuité du sommeil profond.","intensity":55},{"key":"appetite","label":"Appétit","description":"Stimulation de la faim et de l'appréciation gustative (effet « munchies »).","intensity":40},{"key":"uplift","label":"High","description":"Euphorie et intensité sensorielle ; perception du temps et de l'espace modifiée.","intensity":99}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"controlled-named","scheduleLabel":"Stupéfiant : nommément listé","frScheduleStatus":null,"tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":"1971 Schedule II","reference":"CND 62/6 (Mar 2019)","url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"Décision Conseil (UE) 2019/1525","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Annexe IV : listé","reference":"Arrêté 31 mars 2017, NOR AFSP1710288A","url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Adams · NEJM 2017","pmid":"29262413","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/29262413/"},{"label":"Banister · ACS Chem Neurosci 2016","pmid":"27421060","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/27421060/"}],"meta":{"slug":"mmb-fubinaca","url":"https://phytogrammes.com/wiki/mmb-fubinaca","lastVerified":"2026-05-01","dataUpdatedAt":"2026-05-01","confidence":"medium","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}